We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Just more than a year back, the world witnessed a grave health situation arising out of the COVID-19 virus attack. Not just it was unprecedented, it happened all of a sudden, not giving ample time to anyone to take a grasp of the situation.
When does CMI/Compas executive Paul Kallukaran think pharma companies should start looking at using machine learning in their marketing strategies? "Yesterday," he said at a recent digital conference. The good news, however, is that it’s not too late.